tenapanor
Ligand Summary
IBSRELA (tenapanor) tablets contain tenapanor hydrochloride as an active ingredient. Tenapanor hydrochloride is a sodium/hydrogen exchanger 3 (NHE3) inhibitor for oral use, an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. In vitro and animal studies indicate its major metabolite, M1, is not active against NHE3. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, resulting in an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool consistency.
UNII: WYD79216A6
PubChem: 71587953
PubChem: 78131177
Guide to Pharmacology: 8449
ChEMBL: CHEMBL3304485
ChEMBL: CHEMBL3301627
DrugCentral: 5349
LyCHI: WN291L92X1JP
Target Activities
12 Activities
Items per page:
10
1 – 10 of 12
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||